Injectable liposomal docosahexaenoic acid alleviates atherosclerosis progression and enhances plaque stability
Journal of Controlled Release · 2023-08 · 360 · 344-364
DOI: 10.1016/j.jconrel.2023.06.035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2023-08. Verfasst von Suet Yen Chong und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, 119228 Singapore, Singapore; Cardiovascular Research Instit…. Hauptthemen laut MEDLINE: Plaque, Atherosclerotic, Atherosclerosis. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 114 Literaturangaben.
Abstract (Originalsprache)
Atherosclerosis is a chronic inflammatory vascular disease that is characterized by the accumulation of lipids and immune cells in plaques built up inside artery walls. Docosahexaenoic acid (DHA, 22:6n-3), an omega-3 polyunsaturated fatty acid (PUFA), which exerts anti-inflammatory and antioxidant properties, has long been purported to be of therapeutic benefit to atherosclerosis patients. However, large clinical trials have yielded inconsistent data, likely due to variations in the formulation, dosage, and bioavailability of DHA following oral intake. To fully exploit its potential therapeutic effects, we have developed an injectable liposomal DHA formulation intended for intravenous administration as a plaque-targeted nanomedicine. The liposomal formulation protects DHA against chemical degradation and increases its local concentration within atherosclerotic lesions. Mechanistically, DHA liposomes are readily phagocytosed by activated macrophages, exert potent anti-inflammatory and antioxidant effects, and inhibit foam cell formation. Upon intravenous administration, DHA liposomes accumulate preferentially in atherosclerotic lesional macrophages and promote polarization of macrophages towards an anti-inflammatory M2 phenotype, resulting in attenuation of atherosclerosis progression in both ApoE-/- and Ldlr-/- experimental models. Plaque composition analysis demonstrates that liposomal DHA inhibits macrophage infiltration, reduces lipid deposition, and increases collagen content, thus improving the stability of atherosclerotic plaques against rupture. Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) further reveals that DHA liposomes can partly restore the complex lipid profile of the plaques to that of early-stage plaques. In conclusion, DHA liposomes offer a promising approach for applying DHA to stabilize atherosclerotic plaques and attenuate atherosclerosis progression, thereby preventing atherosclerosis-related cardiovascular events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, 119228 Singapore, Singapore; Cardiovascular Research Institute, Yong Loo Lin School of Medicine, National University of Singapore…
- Department of Pharmaceutics, Faculty of Science, Utrecht University, 3584 CG Utrecht, the Netherlands.
- Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, 119228 Singapore, Singapore; Nanomedicine Translational Research Programme, Centre for NanoMedicine, Yong Loo Lin School of Medic…
- Department of Biomedical Engineering, National University of Singapore, 117583 Singapore, Singapore.
- Department of Pharmacy, Faculty of Science, National University of Singapore, 117543 Singapore, Singapore.
- Yong Loo Lin School of Medicine, National University of Singapore, 117599 Singapore, Singapore.
Zitieren
APA
Chong, S. Y., Wang, X., van Bloois, L., Huang, C., Syeda, N. S., Zhang, S., Ting, H. J., Nair, V., Lin, Y., Lou, C. K. L., Benetti, A. A., Yu, X., Lim, N. J. Y., Tan, M. S., Lim, H. Y., Lim, S. Y., Thiam, C. H., Looi, W. D., Zharkova, O., …, & Wang, J. W. (2023). Injectable liposomal docosahexaenoic acid alleviates atherosclerosis progression and enhances plaque stability. Journal of Controlled Release, 360, 344-364. https://doi.org/10.1016/j.jconrel.2023.06.035
Vancouver
Chong SY, Wang X, van Bloois L, Huang C, Syeda NS, Zhang S, et al. Injectable liposomal docosahexaenoic acid alleviates atherosclerosis progression and enhances plaque stability. Journal of Controlled Release. 2023;360:344-364. doi:10.1016/j.jconrel.2023.06.035
BibTeX
@article{Chong2023,
author = {Chong, Suet Yen and Wang, Xiaoyuan and van Bloois, Louis and Huang, Chenyuan and Syeda, Nilofer Sayed and Zhang, Sitong and Ting, Hui Jun and Nair, Vaarsha and Lin, Yuanzhe and Lou, Charles Kang Liang and Benetti, Ayca Altay and Yu, Xiaodong and Lim, Nicole Jia Ying and Tan, Michelle Siying and Lim, Hwee Ying and Lim, Sheau Yng and Thiam, Chung Hwee and Looi, Wen Donq and Zharkova, Olga and Chew, Nicholas W S and Ng, Cheng Han and Bonney, Glenn Kunnath and Muthiah, Mark and Chen, Xiaoyuan and Pastorin, Giorgia and Richards, A Mark and Angeli, Veronique and Storm, Gert and Wang, Jiong-Wei},
title = {Injectable liposomal docosahexaenoic acid alleviates atherosclerosis progression and enhances plaque stability},
journal = {Journal of Controlled Release},
year = {2023},
volume = {360},
pages = {344--364},
doi = {10.1016/j.jconrel.2023.06.035}
}
EUVIMED